MHRA considers Lamisil Once switch
This article was originally published in The Tan Sheet
Executive Summary
Novartis asks the U.K. Medicines and Healthcare products Regulatory Agency to switch Lamisil Once 1% Cutaneous Solution (terbinafine hydrochloride 1 percent) from pharmacy to general sales. MHRA seeks comment on the switch of the athlete's foot treatment for adults 18 years and older, according to a June 8 release. Comments are due July 6. Novartis notes in the application that the product poses only a small health hazard and misuse is low while the incidence of athlete's foot is high